Inventor · disambiguated record
Liang Schweizer
Also filed as: SCHWEIZER LIANG
6 granted patents·19 pending applications·73 citations·filing 2015–2023
84Inventor score
Files withBRISTOL MYERS SQUIBB CO12HIFIBIO HK LTD7HIFIBIO INC4BRISTOL MAYERS SQUIBB COMPANY1HIFIBIO SHANGHAI LTD1
Top patents by PatentIndex Score
25 records- 0197US9605080B2Antibodies against CD73BRISTOL MYERS SQUIBB CO·Filed 2016·Granted Mar 28, 2017·31 cites·30 claims
- 0296US10100129B2Antibodies against CD73 and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2015·Granted Oct 16, 2018·24 cites·35 claims
- 0393US11213586B2Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR)BRISTOL MYERS SQUIBB CO·Filed 2016·Granted Jan 4, 2022·5 cites·14 claims
- 0491US10653791B2Antibodies comprising modified heavy constant regionsBRISTOL MYERS SQUIBB CO·Filed 2015·Granted May 19, 2020·10 cites·6 claims
- 0590US10167343B2Antibodies against CD73BRISTOL MYERS SQUIBB CO·Filed 2017·Granted Jan 1, 2019·3 cites·34 claims
- 0680US2023051701A1Antibodies against cd73 and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2022·Application pending·0 cites
- 0774US2024141059A1Antibodies comprising modified heavy constant regionsBRISTOL MAYERS SQUIBB COMPANY·Filed 2023·Application pending·0 cites
- 0872US11352440B2Antibodies against CD73 and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2018·Granted Jun 7, 2022·0 cites·18 claims
- 0971US2022175921A1Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2021·Application pending·0 cites
- 1064US2019055320A1Antibodies against cd73 and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2018·Application pending·0 cites
- 1160US2020268901A1Antibodies comprising modified heavy constant regionsBRISTOL MYERS SQUIBB CO·Filed 2020·Application pending·0 cites
- 1255US2020299400A1Antibodies comprising modified heavy constant regionsBRISTOL MYERS SQUIBB CO·Filed 2018·Application pending·0 cites
- 1351US2024158517A1Anti-human cxcr5 antibody and uses thereofHIFIBIO HK LTD·Filed 2022·Application pending·0 cites
- 1450US2024317874A1Anti-ox40 monoclonal antibody and methods of use thereofHIFIBIO HK LTD·Filed 2022·Application pending·0 cites
- 1550US2025019451A1Anti-ccr8 antibodies and uses thereofHIFIBIO INC·Filed 2022·Application pending·0 cites
- 1650US2023348891A1Functional screening using droplet-based microfluidicsHIFIBIO SHANGHAI LTD·Filed 2021·Application pending·0 cites
- 1750US2025388673A1Antibody against btla and uses thereofHIFIBIO INC·Filed 2023·Application pending·0 cites
- 1850US2025216382A1Predictive response biomarker discovery processHIFIBIO INC·Filed 2023·Application pending·0 cites
- 1949US2025304693A1Anti-btla antibodies and uses thereof in treating cancerHIFIBIO INC·Filed 2023·Application pending·0 cites
- 2046US2023045791A1Anti-tnfr2 antibody and uses thereofHIFIBIO HK LTD·Filed 2021·Application pending·0 cites
- 2146US2023227539A1Methods and compositions related to neutralizing antibodies against human coronavirusHIFIBIO HK LTD·Filed 2021·Application pending·0 cites
- 2246US2023160009A1Predictive response biomarker discovery processHIFIBIO HK LTD·Filed 2021·Application pending·0 cites
- 2345US2023054718A1Anti-galectin-9 antibody and uses thereofHIFIBIO HK LTD·Filed 2021·Application pending·0 cites
- 2445US2023061604A1Anti-ox40 antibody and use thereofHIFIBIO HK LTD·Filed 2020·Application pending·0 cites
- 2538US2019284293A1Combination therapy with anti-cd73 antibodiesBRISTOL MYERS SQUIBB CO·Filed 2017·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Liang Schweizer files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →